Weight Loss and Blood Sugar Control in Type 2 diabetes with GLP-1 Agonist Therapy

At the General Electric Centricity research using medical records were analyzed retrospectively to evaluate the relationship between body weight and blood sugar control as well as changes in blood pressure and lipids in patients with type 2 diabetes who received exenatide therapy, sitagliptin, or insulin. Baseline and follow-up (90 -365 days after the date of the index) to body weight, A1C, fasting blood glucose (FBG), blood pressure, triglycerides, and LDL, HDL, and total cholesterol were assessed.

The results: A total of 6280, 5861, and 32,398 patients who received exenatide, sitagliptin, or insulin, respectively were analyzed. Weight loss in patients treated with exenatide, the mean SD 3.0 ± 7.33 kg, the weight loss in patients treated with sitagliptin, a mean SD 1.1 ± 5.39 kg and insulin-treated patients gained 0.6 ± 9.49 kg. There was a significant relationship between weight loss with a reduction in A1C levels and GDP in the exenatide treatment and decreased blood pressure for all therapies. Weight loss associated with improvements in lipid levels, especially in the GLP-1 receptor agonists, and relationships that small groups of insulin.
source : Diabetes Care 33:1759–1765,
Conclusion: Weight loss in patients with type 2 diabetes can improve blood sugar control, lowering blood pressure and improve dyslipidemia. Glucagon Like Peptide receptor agonists (GLP-1) associated with weight loss
Judul: Weight Loss and Blood Sugar Control in Type 2 diabetes with GLP-1 Agonist Therapy; Ditulis oleh Hery IMG; Rating Blog: 5 dari 5

Tidak ada komentar:

Poskan Komentar

Silahkan Memberi Tanggapan Atau Komentar, Kometar Spam akan Kami Hapus.